Suven Life Sciences FY26 Results Ad Published; Wider Net Loss Amid R&D Push
Suven Life Sciences published newspaper advertisements for its audited FY26 financial results on May 14, 2026, per Regulation 47 of SEBI (LODR) Regulations, 2015. The consolidated net loss widened to ₹2,763.44 million in FY26 from ₹1,607.45 million in FY25, while standalone net loss stood at Rs. 5,486.28 lakhs. The company's Phase 3 Masupirdine trial reached 76% enrollment, and its preferential issue received Rs. 76,432.53 lakhs against total proceeds of Rs. 85,764 lakhs.
*this image is generated using AI for illustrative purposes only.
Suven Life Sciences announced its audited financial results for the quarter and year ended March 31, 2026, at its Board of Directors meeting held on May 13, 2026, in Hyderabad. Pursuant to Regulation 47 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements regarding these audited financial results on May 14, 2026, in Andhra Prabha (Telugu) and Business Standard. The advertisements are also hosted on the company's website at www.suven.com/newspaperads.aspx . The results were reviewed by the Audit Committee and approved by the Board under Regulation 33 of the SEBI (LODR) Regulations, 2015.
Consolidated Financial Performance
The company reported a consolidated net loss of ₹2,763.44 million for the financial year, compared to a net loss of ₹1,607.45 million in the previous year. Revenue from operations for the year increased to ₹210.45 million from ₹175.53 million in FY25. For the quarter ended March 31, 2026, the company posted a net loss of ₹455.96 million on revenue of ₹82.98 million. The company's R&D and operational expenses for the year stood at ₹2,916.18 million, reflecting its continued investment in drug discovery and development. The following table summarises the key consolidated financial metrics:
| Metric: | FY26 (₹ Mn) | FY25 (₹ Mn) |
|---|---|---|
| Revenue from Operations: | 210.45 | 175.53 |
| R&D and Operational Expenses: | 2,916.18 | 1,724.29 |
| Depreciation and Amortisation: | 56.14 | 58.22 |
| Finance Cost: | 1.58 | 0.47 |
| Net Profit/(Loss): | (2,763.44) | (1,607.45) |
| Other Comprehensive Income: | (11.84) | (5.83) |
| Total Comprehensive Income/(Loss): | (2,775.28) | (1,613.28) |
| EPS – Basic & Diluted (₹): | (12.13) | (7.37) |
Standalone Financial Performance
On a standalone basis, Suven Life Sciences reported revenue from operations of Rs. 711.47 lakhs for the year ended March 31, 2026, compared to Rs. 665.58 lakhs in the previous year. The standalone net loss for the year stood at Rs. 5,486.28 lakhs, against Rs. 4,707.98 lakhs in FY25. Total standalone expenses for the year were Rs. 7,588.80 lakhs, with R&D expenses at Rs. 2,797.24 lakhs and employee benefits expense at Rs. 2,414.94 lakhs. Standalone basic and diluted EPS for the year was Rs. (2.41), compared to Rs. (2.16) in FY25. The newspaper advertisement published in Business Standard also disclosed the following summary of standalone and consolidated financial results:
| Particulars: | Standalone – Year Ended 31/03/2026 (Rs. Lakhs) | Consolidated – Year Ended 31/03/2026 (Rs. Lakhs) |
|---|---|---|
| Total Income from Operations: | 711.47 | 711.47 |
| Net Profit/(Loss) After Tax: | (5,486.28) | (27,634.41) |
| Total Comprehensive Income/(Loss): | (5,508.47) | (27,752.80) |
| Equity Share Capital: | 2,637.20 | 2,637.20 |
| Other Equity (excl. Revaluation Reserve): | 1,47,699.51 | 56,502.76 |
| EPS – Basic & Diluted (Rs. 1/- each): | (2.41) | (12.13) |
| Metric: | FY26 (Rs. Lakhs) | FY25 (Rs. Lakhs) |
|---|---|---|
| Revenue from Operations: | 711.47 | 665.58 |
| Employee Benefits Expense: | 2,414.94 | 2,082.49 |
| R&D Expenses: | 2,797.24 | 3,043.16 |
| Depreciation and Amortisation: | 561.35 | 582.17 |
| Total Expenses: | 7,588.80 | 6,446.15 |
| Net Loss: | (5,486.28) | (4,707.98) |
| EPS – Basic & Diluted (Rs.): | (2.41) | (2.16) |
Preferential Issue and Capital Activity
The Board of Directors approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees, with each warrant convertible into one equity share of face value ₹1/- at an exercise price of ₹134/- per share, within 18 months from the date of allotment. Out of the total issue proceeds of Rs. 85,764 lakhs, Rs. 76,432.53 lakhs has been received, while Rs. 9,331 lakhs is yet to be received from warrant holders. During the period from July 2025 to March 2026, the company allotted 4,54,32,866 equity shares on conversion of an equivalent number of fully paid warrants to six allottees, upon receipt of 100% of the warrant consideration amounting to Rs. 60,880.04 lakhs.
| Particulars: | Rs. In Lakhs |
|---|---|
| Amount Received through Preferential Issue: | 76,432.53 |
| Less: Amount Utilised: | 26,068.64 |
| Balance Amount: | 50,363.89 |
Corporate Governance and AGM
The Board noted the acceptance of a waiver of fines by BSE, as communicated vide email dated April 23, 2026, in respect of penal actions imposed for non-compliance with Regulation 19 of the SEBI (LODR) Regulations, 2015 pertaining to a prior period. The outcome of a similar waiver application from NSE is still pending. The Board advised management to exercise greater diligence in ensuring strict compliance with regulations and also recommended seeking external professional advice in cases of ambiguity or uncertainty in the interpretation of applicable regulations. Additionally, the company scheduled its 37th Annual General Meeting for August 25, 2026, via video conferencing.
Clinical Pipeline Update
Suven provided updates on its clinical-stage assets spanning multiple CNS disorders. The company also granted 7 patents during the period covering countries ARIPO, EPO, Japan, and Mexico. The following table summarises the status of each pipeline asset:
| Asset: | Details |
|---|---|
| SUVN-502 (Masupirdine): | Global Phase 3 study for agitation in Alzheimer's dementia — 76% enrollment milestone achieved; patient enrollment completion expected by end of calendar 2026; data readout expected in Q2/Q3 of calendar 2027 |
| SUVN-G3031 (Samelisant): | Global Phase 3 clinical study for treatment of excessive daytime sleepiness (EDS) in narcolepsy initiated in April 2026 |
| SUVN-911 (Ropanicant): | Phase 2B clinical study in USA is complete; data readout expected soon |
| SUVN-D4010 (Usmarapride): | New IND submission made with FDA for Phase 2 proof-of-concept study for treatment of cognitive dysfunction in adults with major depressive disorder (MDD); Phase 2 double-blind study to start during calendar 2026 |
| SUVN-I6107: | Phase 1 study for establishing safety and pharmacokinetics completed; preparing for Phase 2 clinical study |
Historical Stock Returns for Suven Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.54% | -3.27% | +8.48% | +12.99% | +20.56% | +120.56% |
If SUVN-502 (Masupirdine) fails to meet primary endpoints in its Phase 3 Alzheimer's agitation trial, how would Suven Life Sciences sustain operations given its rapidly widening net losses and heavy R&D burn rate?
With ₹50,363.89 lakhs in unutilised preferential issue proceeds, how is management prioritizing capital allocation across the five clinical-stage pipeline assets to maximize the probability of a successful data readout?
Given the pending NSE waiver application for regulatory non-compliance and the Board's acknowledgment of governance lapses, what structural changes to compliance oversight could impact investor confidence and future fundraising ability?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
